Cargando…
Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients
BACKGROUND: Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this study was to investigate whether...
Autores principales: | Viller Tuxen, Ida, Barlebo Ahlborn, Lise, Mau-Soerensen, Morten, Staal Rohrberg, Kristoffer, Cilius Nielsen, Finn, Oestrup, Olga, Westmose Yde, Christina, Richter Vogelius, Ivan, Lassen, Ulrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738043/ https://www.ncbi.nlm.nih.gov/pubmed/31186525 http://dx.doi.org/10.1038/s41416-019-0491-9 |
Ejemplares similares
-
Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors
por: Ahlborn, Lise Barlebo, et al.
Publicado: (2018) -
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer
por: Bertelsen, Birgitte, et al.
Publicado: (2019) -
Detection of copy number alterations in cell-free tumor DNA from plasma
por: Østrup, Olga, et al.
Publicado: (2017) -
Application of cell-free DNA for genomic tumor profiling: a feasibility study
por: Ahlborn, Lise B., et al.
Publicado: (2019) -
Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study
por: Nørøxe, Dorte Schou, et al.
Publicado: (2019)